Notice: This company has been marked as potentially delisted and may not be actively trading. Stellar Biotechnologies (SBOT) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends SBOT vs. TRVI, DRUG, PEPG, NBTX, CRBP, SCPH, CYBN, PGEN, GOSS, and FULCShould you be buying Stellar Biotechnologies stock or one of its competitors? The main competitors of Stellar Biotechnologies include Trevi Therapeutics (TRVI), Bright Minds Biosciences (DRUG), PepGen (PEPG), Nanobiotix (NBTX), Corbus Pharmaceuticals (CRBP), scPharmaceuticals (SCPH), Cybin (CYBN), Precigen (PGEN), Gossamer Bio (GOSS), and Fulcrum Therapeutics (FULC). These companies are all part of the "medical" sector. Stellar Biotechnologies vs. Trevi Therapeutics Bright Minds Biosciences PepGen Nanobiotix Corbus Pharmaceuticals scPharmaceuticals Cybin Precigen Gossamer Bio Fulcrum Therapeutics Stellar Biotechnologies (NASDAQ:SBOT) and Trevi Therapeutics (NASDAQ:TRVI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, community ranking, media sentiment, valuation, profitability and risk. Is SBOT or TRVI more profitable? Trevi Therapeutics has a net margin of 0.00% compared to Stellar Biotechnologies' net margin of -1,782.64%. Trevi Therapeutics' return on equity of -49.92% beat Stellar Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets Stellar Biotechnologies-1,782.64% -51.12% -48.37% Trevi Therapeutics N/A -49.92%-45.93% Do analysts rate SBOT or TRVI? Trevi Therapeutics has a consensus price target of $7.43, suggesting a potential upside of 146.80%. Given Trevi Therapeutics' higher probable upside, analysts plainly believe Trevi Therapeutics is more favorable than Stellar Biotechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Stellar Biotechnologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/ATrevi Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22 Does the MarketBeat Community favor SBOT or TRVI? Stellar Biotechnologies received 147 more outperform votes than Trevi Therapeutics when rated by MarketBeat users. Likewise, 66.48% of users gave Stellar Biotechnologies an outperform vote while only 63.50% of users gave Trevi Therapeutics an outperform vote. CompanyUnderperformOutperformStellar BiotechnologiesOutperform Votes23466.48% Underperform Votes11833.52% Trevi TherapeuticsOutperform Votes8763.50% Underperform Votes5036.50% Does the media refer more to SBOT or TRVI? In the previous week, Trevi Therapeutics had 3 more articles in the media than Stellar Biotechnologies. MarketBeat recorded 3 mentions for Trevi Therapeutics and 0 mentions for Stellar Biotechnologies. Trevi Therapeutics' average media sentiment score of 0.14 beat Stellar Biotechnologies' score of 0.00 indicating that Trevi Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Stellar Biotechnologies Neutral Trevi Therapeutics Neutral Do insiders & institutionals believe in SBOT or TRVI? 1.7% of Stellar Biotechnologies shares are owned by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are owned by institutional investors. 7.8% of Stellar Biotechnologies shares are owned by company insiders. Comparatively, 24.4% of Trevi Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has higher earnings and valuation, SBOT or TRVI? Stellar Biotechnologies has higher revenue and earnings than Trevi Therapeutics. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Stellar Biotechnologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStellar Biotechnologies$210K254.82-$5.03M-$1.76-5.70Trevi TherapeuticsN/AN/A-$29.07M-$0.39-7.72 SummaryTrevi Therapeutics beats Stellar Biotechnologies on 11 of the 16 factors compared between the two stocks. Ad Porter & CompanyTrue paradigm shiftI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. Here’s the full story for you. Get Stellar Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for SBOT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SBOT vs. The Competition Export to ExcelMetricStellar BiotechnologiesPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$53.51M$7.42B$5.50B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E Ratio-5.7010.05116.1015.23Price / Sales254.82400.761,496.2597.74Price / CashN/A47.3939.7434.10Price / Book4.745.594.775.07Net Income-$5.03M$153.56M$119.06M$225.46M Stellar Biotechnologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SBOTStellar BiotechnologiesN/A$10.04-0.9%N/A+213.8%$53.51M$210,000.00-5.7025Gap UpTRVITrevi Therapeutics3.6138 of 5 stars$3.01+2.0%$7.43+146.8%+71.0%$213.78MN/A-7.7220Upcoming EarningsNews CoverageDRUGBright Minds Biosciences1.1958 of 5 stars$48.18+2.9%N/A+3,416.8%$213.44MN/A-70.85N/APEPGPepGen2.5419 of 5 stars$6.48-2.1%$19.33+198.4%+27.1%$211.18MN/A-1.9672NBTXNanobiotix2.3656 of 5 stars$4.40+5.8%$11.50+161.4%-29.1%$207.37M$39.18M0.00100News CoveragePositive NewsCRBPCorbus Pharmaceuticals4.4642 of 5 stars$16.92+6.0%$65.86+289.2%+235.0%$203.78M$880,000.00-2.9140Upcoming EarningsShort Interest ↑SCPHscPharmaceuticals3.5044 of 5 stars$4.07-1.9%$18.00+342.3%-22.2%$203.62M$24.05M-2.6130CYBNCybin1.8174 of 5 stars$9.99-0.4%$50.50+405.5%N/A$199.72MN/A-1.6450PGENPrecigen4.3121 of 5 stars$0.82+3.8%$7.00+757.0%-23.7%$199.23M$6.22M-1.51202Positive NewsGOSSGossamer Bio4.4818 of 5 stars$0.87flat$9.20+953.0%+82.0%$197.66MN/A-2.24180Short Interest ↓Positive NewsFULCFulcrum Therapeutics3.4943 of 5 stars$3.21+1.6%$9.33+190.8%-14.4%$197.19M$81.63M-9.17100Upcoming EarningsShort Interest ↓Positive News Related Companies and Tools Related Companies TRVI Competitors DRUG Competitors PEPG Competitors NBTX Competitors CRBP Competitors SCPH Competitors CYBN Competitors PGEN Competitors GOSS Competitors FULC Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SBOT) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stellar Biotechnologies Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Stellar Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
